Slow-K

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Slow-K

Property Description
Active ingredient Potassium Chloride (KCl)
Form Extended-release tablet (Slow-release formulation)
Pharmacological class Electrolyte Replacement / Mineral Supplement
Common use Maintaining electrolyte balance
Origin Synthetic (Inorganic salt)

What is Slow-K and Its Pharmacological Identity?

Slow-K is the trade name for a prescription-only medication whose active ingredient is Potassium Chloride (KCl). This compound is formally classified as an Electrolyte Replacement and Mineral Supplement. The Slow-K brand is recognized for its unique form: an extended-release tablet, a specialized type of oral tablet known as a slow-release formulation. This specific design, which incorporates an inert solid matrix or coating, is clinically recognized for its controlled delivery, a method intended to reduce the possibility of high localized concentrations compared to standard immediate-release forms.


Composition: Active Ingredient and Origin

The formulation of Slow-K is a single-ingredient product, containing only the inorganic salt Potassium Chloride as its therapeutic component. This compound supplies both the essential electrolyte Potassium and the Chloride ion, both critical for maintaining the body's electrochemical balance. Although potassium is a naturally occurring essential mineral, the substance used in this preparation is produced industrially, classifying the product’s origin as synthetic. The focus on a Potassium Chloride base, rather than salts like potassium gluconate or citrate, is standard practice for electrolyte replacement therapy where both ions are required.


General Purpose: Why is Potassium Chloride Essential?

The fundamental general purpose of this medication is to serve as a reliable source of Potassium to prevent or correct the state of hypokalemia, or low potassium levels in the bloodstream. A typical neutral use scenario involves individuals who require consistent supplementation due to conditions that cause excessive potassium loss, such as those on certain diuretic medications. By restoring this crucial electrolyte, the medication supports essential biological processes. Potassium is integral to the maintenance of proper nerve impulse transmission, facilitates efficient muscle contraction, and functions as a key component in cardiac function by controlling the heart's rhythmic electrical signals.

What side effects are possible with Slow-K?

Possible Side Effects and Safety Information

Slow-K (potassium chloride extended-release tablets) is generally well-tolerated, but like all medications, it can cause side effects. Most common side effects relate to gastrointestinal (GI) irritation and can often be minimized by taking the tablet with food or immediately after a meal, as directed by a healthcare professional.


Common Side Effects

These side effects are generally mild and may resolve as the body adjusts to the medication. Consult your doctor if these symptoms persist or become bothersome:

  • Nausea and vomiting
  • Diarrhea
  • Gas or flatulence
  • Stomach discomfort or abdominal pain

Serious Warnings and Adverse Reactions

Hyperkalemia (high potassium levels) is the most serious potential side effect and can be life-threatening, even without symptoms. The risk is higher in individuals with impaired kidney function or those taking certain other medications (such as potassium-sparing diuretics or ACE inhibitors). Your doctor will perform regular blood tests to monitor your potassium levels.

Seek immediate medical attention if you experience signs of hyperkalemia, which may include:

  • Unusual tiredness or weakness
  • Slow or irregular heartbeat
  • Muscle weakness or unusual heaviness in the legs
  • Tingling or numbness

Gastrointestinal Complications: Solid oral potassium chloride formulations, including Slow-K, have been associated with reports of ulceration, bleeding, obstruction, or perforation in the stomach or intestines. Stop taking Slow-K and seek emergency care if you experience:

  • Severe vomiting, or vomiting blood/material that looks like coffee grounds
  • Black, tarry, or bloody stools
  • Severe, persistent stomach pain or bloating
  • Difficulty or pain when swallowing, or feeling like the tablet is stuck in your throat

It is normal to occasionally see the wax matrix of the extended-release tablet in the stool; the potassium has been absorbed by the body.


Safety Precautions and Contraindications

Do not take Slow-K if you have a condition that causes high potassium levels (hyperkalemia) or if you are allergic to any of the ingredients. Always inform your healthcare provider about your complete medical history, especially conditions affecting the kidneys, heart, or gastrointestinal tract, and all other medications, supplements, and salt substitutes you are taking.

Overdose and Emergency Response

The regulatory overdose profile for Slow-K (Potassium Chloride) is centered on the risk of hyperkalemia, which is an excessive concentration of potassium in the blood. Overdose presentations range from asymptomatic elevation of serum potassium, detectable only through laboratory tests and characteristic Electrocardiogram (ECG) changes, to severe systemic toxicity. Clinical manifestations include progressive neuromuscular dysfunction, such as muscle weakness and flaccid paralysis. The most severe outcomes are linked to the cardiovascular system, where hyperkalemia can lead to cardiac arrhythmias, cardiovascular collapse, and ultimately cardiac arrest.

The risk of potentially fatal hyperkalemia is substantially increased in individuals with impaired renal function due to the inability to excrete the mineral. Immediate medical attention is required for any suspected overdose or the onset of severe symptoms like irregular heartbeats, chest pain, or loss of movement. Additionally, the medication must be discontinued immediately if signs of severe gastrointestinal effects, such as bleeding or severe abdominal pain, are present. Management of overdose requires continuous cardiac monitoring and the institution of corrective therapy to reduce serum potassium concentrations.

Therapeutic Uses of Slow-K

Quick Facts: Slow-K Therapeutic Overview

Domain Statement
Primary Use Supports the management of low blood potassium levels (hypokalemia).
Preventative Use May assist in preventing potassium deficiency when diet is insufficient.
Associated Condition Supports potassium levels in patients concurrently managing metabolic alkalosis.

What Slow-K Treats: Main Uses and Benefits

Slow-K is a medication utilized to support the maintenance of adequate potassium levels in the body. Its primary role involves the treatment of hypokalemia, a condition characterized by a low concentration of potassium in the bloodstream. Maintaining appropriate potassium levels is crucial for essential physiological function.

This medication is also frequently used for the prevention of potassium depletion in individuals whose dietary intake of potassium may be insufficient to meet their needs. This prophylactic use is commonly indicated for patients concurrently using diuretics or those who are managing certain heart conditions, where potassium loss may occur. Furthermore, it is suitable for the clinical management of potassium depletion when it occurs alongside metabolic alkalosis.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Slow-K is a prescription medicine that can be used by adults who do not have specific health conditions or who are not taking certain medications that make its use contraindicated or require special caution. Eligibility is strictly defined by official regulatory labeling, focusing on the potential for hyperkalemia (high potassium) and gastrointestinal complications.

Contraindicated Populations

Use of Slow-K is contraindicated (prohibited) for individuals with:

  • Pre-existing high potassium levels in the blood (hyperkalemia) or conditions that greatly increase this risk, such as severe renal impairment (kidney failure), untreated Addison's disease, or extensive tissue breakdown (e.g., severe burns).
  • Conditions predisposing to obstruction or perforation of the gastrointestinal (GI) tract, as the solid oral tablet formulation can be irritating.
  • Concurrent use of potassium-sparing diuretics (such as spironolactone, amiloride, or triamterene).

Restricted Use and Special Consideration

Use of Slow-K requires caution and close monitoring for patients with mild-to-moderate renal impairment, hepatic impairment, or in older adults (aged 65 and over) due to the increased risk of hyperkalemia. Safety and effectiveness in pediatric patients have not been established, and therefore its use is not generally recommended in children. The medicine is not typically classified as contraindicated during pregnancy or lactation in the eligibility sections, but the decision to use it must be made by a healthcare professional after weighing the clinical benefit.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Slow-K (Potassium Chloride extended-release) is primarily defined by the risk of hyperkalemia (elevated serum potassium levels) and restrictions related to its solid oral dosage form.


Contraindicated Combinations

Co-administration is officially contraindicated with two primary categories of agents, as documented in regulatory labeling:

  • Potassium-Sparing Diuretics: Medicines such as triamterene and amiloride are strictly prohibited due to the severe and additive risk of hyperkalemia.
  • Anticholinergic Agents: Solid oral dosage forms are contraindicated when used concurrently with medicines that possess strong anticholinergic properties, or any condition documented to cause significant delay in the tablet's passage through the gastrointestinal (GI) tract. This restriction is a physical constraint intended to prevent localized tissue injury from prolonged contact.

Other Clinically Relevant Interactions

Interactions requiring close monitoring due to their potential to cause potassium retention include co-administration with Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors (e.g., ACE Inhibitors, ARBs), Aldosterone Receptor Antagonists, and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). All potassium-containing salt substitutes or other potassium supplements must be avoided due to the additive risk of hyperkalemia. Additionally, potassium chloride can cause a cation binding interaction in the GI tract, which is documented to decrease the exposure and effect of certain co-administered drugs, such as Baloxavir Marboxil.

Population-Specific Notes

The documented risk of severe reactions from these interactions is noted to be greater in patients with impaired renal function.

Mechanism of Action

How Slow-K Works

Slow-K's mechanism of action is rooted in restoring cellular potassium homeostasis by providing absorbed potassium ions (K^+). These ions are essential for the Na^+/ K^+-ATPase pump, the primary biological target responsible for maintaining the electrochemical gradients across all cell membranes. The delivery of K^+ replenishes the systemic electrolyte pool, supporting the necessary conditions for metabolic and physiological processes.

Regulation of Electrical Excitability

The replenished potassium concentration is the principal factor establishing the resting membrane potential in excitable tissues, including nerve cells and myocytes. By normalizing the K^+ gradient, the drug supports the appropriate sequence of depolarization and repolarization necessary for electrical impulse conduction. This mechanism modulates transmembrane potential, supporting the establishment of consistent cellular excitability and effective myocardial and skeletal muscle depolarization.

Controlled Gastrointestinal Delivery

Additionally, the drug's formulation employs a slow-release wax matrix. This physical mechanism controls the rate at which potassium chloride dissolves in the gastrointestinal tract. This dissolution profile influences the localized salt concentration and the gastrointestinal mucosa's exposure to the compound.

Dosage and Administration Information

Slow-K (potassium chloride extended-release tablets) should be taken exactly as prescribed by your healthcare provider. The dosage is individualized based on the patient's specific needs, including the severity of potassium deficiency, which is determined by monitoring serum potassium levels. For the prevention of hypokalemia, the typical adult dose is often around 20 mEq per day. For the treatment of potassium depletion, doses typically range from 40 to 100 mEq per day.


Administration Guidelines

To minimize the potential for gastric irritation and serious gastrointestinal issues, adhere strictly to the following administration guidelines:

  • Swallow Whole: The extended-release tablet must be swallowed whole. Do not crush, chew, or suck the tablet. Crushing the tablet can release the potassium too rapidly, increasing the risk of adverse effects.
  • Take with Food and Liquid: Always take Slow-K with a full glass of water or other liquid and with a meal or immediately after eating. Do not take it on an empty stomach.
  • Divided Doses: If your total daily dose is greater than 20 mEq, it should be divided throughout the day. Do not take more than 20 mEq in a single dose unless specifically instructed otherwise by your doctor.

If you have difficulty swallowing the tablet or feel that it is stuck in your throat, contact your healthcare professional immediately. Monitoring of serum potassium levels is essential throughout your treatment to ensure the dose is effective and to avoid the risk of hyperkalemia (high potassium levels).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Slow-K

Research Evidence for Using Slow-K to Correct Low Potassium

The primary area for which extended-release potassium chloride was studied for its role in the context of low blood potassium levels, a condition known as hypokalemia. Research explored this through different study designs. Scientists conducted randomized controlled trials (RCTs) which was used to explore the extended-release tablet formulation against other forms of potassium, such as liquids or immediate-release tablets. Furthermore, pharmacokinetic (PK) studies were applied to examine how the body absorbs and processes the medication over defined time intervals.

Research examined the effect on a key measure: the serum potassium concentration (K^+). This biomarker is used to reflect the level of potassium in the bloodstream. Findings describe patterns observed in the studies, indicating the research monitored changes in this biochemical endpoint. The populations evaluated in these studies included adults with mild to moderate hypokalemia. What remains uncertain is the impact on long-term health outcomes, as the research has historically focused on the serum potassium level, a surrogate biomarker.

Study Focus: Comparing Formulations and Delivery

Comparative research examined the extended-release tablet delivery system. These studies were used to explore how the controlled-release formula may affect absorption compared to non-retard forms. Specifically, PK studies research examined the amount of potassium excreted in the urine over 24 or 48 hours to explore patterns of delivery. This research provides context regarding the tablet's property of slow delivery, which is relevant in evidence describing the characteristics of the tablet’s slow-release delivery.


Research Evidence for Preventing Potassium Depletion

Research explored the role of extended-release potassium chloride in the context of preventing potassium depletion in individuals whose underlying conditions or medications cause ongoing potassium loss. This prophylactic use was evaluated in observational and cohort studies, which were used to explore patterns in high-risk populations. Studies monitored the serum potassium levels to assess how the levels evolved within the context of the study. The existing evidence contributes to the broader evidence landscape for this replacement therapy.

Research limitation frames indicate that few dedicated large-scale RCTs have studied for the impact of prophylactic supplementation on preventing complex, downstream outcomes over many years. While research describes the ability to maintain the biomarker level, comparative evidence is lacking regarding the long-term monitoring of this strategy.

Key Studies & References

  1. Potassium Chloride Extended-Release Tablets USP, 8 mEq (600 mg) Labeling Information (e.g., K-Tab or Slow-K Regulatory Data)
  2. NIH MedlinePlus Drug Information: Potassium Chloride Oral

Frequently Asked Questions (FAQ)

Common questions about Slow-K (FAQ)

Q: How long does it take for Slow-K to start working after I take it?

Slow-K is manufactured as an extended-release formulation. This means the tablet is designed to deliver the potassium chloride slowly and continuously over time as it moves through the digestive tract. The slow-release mechanism is intended to avoid high, localized concentrations of potassium in the gut.

Q: How long does the effect of one dose of Slow-K last?

The extended-release tablet is engineered to deliver potassium over an extended period. Because daily doses over 20 mEq are typically divided and taken throughout the day, the extended-release formulation is designed to support the prescribed daily regimen, which typically involves divided doses.

Q: Can Slow-K interact with common pain relievers like ibuprofen?

According to official product information, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are a class of medicine that requires caution and close monitoring when used with potassium chloride. This is due to the potential for an additive effect that could lead to elevated potassium levels in the blood (hyperkalemia).

Q: Can I take Slow-K with vitamins or other supplements?

Official documents strictly state that all other potassium supplements must be avoided. This also includes potassium-containing salt substitutes. Official sources state that combining these products may raise the risk of excessively high potassium levels in the blood.

Q: Does Slow-K interact with common heart medicines?

Yes, official labeling indicates that certain medicines commonly used for heart or blood pressure conditions can interact. Specifically, medicines like ACE Inhibitors, ARBs, and potassium-sparing diuretics may increase the risk of hyperkalemia and require close monitoring.

Q: How does taking Slow-K compare to just eating potassium-rich foods?

Slow-K is an electrolyte replacement that provides a synthetic, measured dose of potassium chloride salt. This differs from the potassium obtained naturally from food sources. The dose and controlled-release nature of the tablet are specifically intended to treat or prevent low potassium levels.

Q: Is Slow-K a type of essential mineral?

Yes. The active ingredient in Slow-K is Potassium Chloride, which provides Potassium. Potassium is classified as an essential mineral and electrolyte, necessary for maintaining the body's electrochemical balance and for proper nerve and muscle function.

Q: Can Slow-K be used to prevent a drop in potassium, or is it only for treatment?

Official indications show the medication is used both for the treatment of existing low potassium levels (hypokalemia) and for the prevention of potassium depletion in individuals whose conditions or medications put them at risk.

Q: Is Slow-K the same thing as a potassium supplement I can buy over the counter?

No. Slow-K is a prescription-only medication classified as an electrolyte replacement. It is not equivalent to the smaller-dose potassium supplements that can be purchased over the counter.

Q: Do I need a prescription to get Slow-K?

Official product information classifies Slow-K as a prescription-only medication.

Q: What happens if I miss a dose of Slow-K?

Official patient information describes that if a dose is missed, it can be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. It is important that users do not take double or extra doses to make up for a missed one.

Q: Does Slow-K make you tired or dizzy?

Tiredness or dizziness are not typically listed as common side effects of the medication. However, feeling unusually tired, weak, or dizzy can be a potential sign of hyperkalemia (excessively high potassium), a serious adverse reaction that requires immediate attention.

Q: Are there foods I should avoid while using Slow-K?

Official information requires the tablet to be taken with a meal. Beyond this, the only food-related item that is strictly prohibited is salt substitutes that contain potassium, as these will contribute to the total potassium load.

Q: Is Slow-K a diuretic (water pill)?

No. Slow-K is formally classified as an Electrolyte Replacement and a Mineral Supplement. It is not a diuretic (water pill), although it is commonly used to replace the potassium that can be lost when taking certain diuretic medicines.

Q: Can I take Slow-K if I have diabetes?

Official labeling mentions that certain conditions associated with diabetes can affect the use of this medication. For example, diabetic acidosis or conditions that slow down the gut's movement (diabetic gastroparesis) may complicate or contraindicate its use.

Q: Is Slow-K known to cause skin rashes or allergic reactions?

Official safety reports list skin rash as a reported adverse reaction. Additionally, signs of an allergic reaction are cited in warnings as reasons to seek immediate medical attention.

Q: What should I know about using Slow-K with salt substitutes?

Regulatory documents explicitly prohibit the use of potassium-containing salt substitutes. This is because these substitutes increase the total potassium load in the body, which significantly raises the risk of developing hyperkalemia (dangerously high potassium levels).

Q: Are there any specific safety warnings for children taking Slow-K?

Official regulatory documents state that the safety and effectiveness in pediatric patients have not been established. Therefore, the medication is not generally recommended for use in children.

Q: What are the signs that Slow-K is working as intended?

The effectiveness of the medication cannot be determined by subjective feelings or physical signs. The only way to confirm the medication is working as intended is through a healthcare professional monitoring serum potassium concentrations (potassium levels in the blood) via regular blood tests.

Q: What happens if I use Slow-K and I don't actually have low potassium?

Official regulatory warnings note that using the medication when a deficiency is not present carries the risk of hyperkalemia (high potassium levels), which is listed as a serious adverse reaction.

Q: Are there any drug classes that commonly interact with Slow-K?

The primary drug classes that interact are those that also affect potassium levels, such as potassium-sparing diuretics and RAAS inhibitors. Additionally, drugs that slow down gut transit, such as certain anticholinergic agents, are also noted for potential interaction risks.

Q: Does Slow-K contain any common allergens like gluten or lactose?

The inactive ingredients listed in the formulation include sucrose, starch, and gelatin. Specific information on the presence or absence of gluten or lactose is not uniformly documented in the official labeling.

Q: Why do some people refer to Slow-K as a salt tablet?

Slow-K contains Potassium Chloride, which is an inorganic salt used as an electrolyte replacement. This chemical composition is the factual basis for the common, colloquial term 'salt tablet'.

Q: Are there different strengths of Slow-K tablets available?

According to official documentation, the most commonly available tablet strength for the Slow-K brand is 8 mEq (600 mg) of potassium chloride.

Q: Does the efficacy of Slow-K vary based on a patient's diet?

Official documents indicate that a patient’s diet is relevant to the required dose, noting that if the diet is rich in natural sources of potassium, dosage may be a factor for consideration.

Q: Can taking Slow-K cause digestive issues other than nausea?

The reported common digestive issues include nausea, vomiting, diarrhea, gas, and general stomach discomfort or abdominal pain. Official guidance on administration suggests taking the tablet with a full meal, a measure that is intended to help minimize gastrointestinal side effects.

How should Slow-K be stored and disposed of?

How to Store and Dispose of Slow-K (Official Regulatory Requirements)

Slow-K (potassium chloride extended-release tablets) must be stored and disposed of according to strict regulatory guidelines to maintain product quality and ensure environmental safety.


Storage Conditions

  • Temperature: Store at a Controlled Room Temperature between 20 C and 25 C (68 F and 77 F). Do not store above 30 C.
  • Container: The tablets must be kept in the original container and the container must remain tightly closed.
  • Child Safety: Keep the medication out of the sight and reach of children.

Disposal Instructions

  • Method: Do not dispose of via wastewater or household garbage.
  • Procedure: Return unused or expired Slow-K tablets to a pharmacist or pharmaceutical waste collection point for appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Slow-K found in:

A-Z Index: